Bimatoprost is under clinical development by Laboratoires Thea and currently in Phase III for Open-Angle Glaucoma. According to GlobalData, Phase III drugs for Open-Angle Glaucoma have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Bimatoprost’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bimatoprost (T-4032) is under development for the treatment of open-angle glaucoma and ocular hypertension. It is administered by ophthalmic route as drops. It acts by targeting prostaglandin F2 alpha.
Laboratoires Thea overview
Laboratoires Thea (Thea) is pharmaceutical company that researches, develops, manufactures, and commercializes a wide variety of eye care products. The company’s products find application in the diagnosis, surgery and treatment of ophthalmic diseases such as dry eye, allergies, glaucoma, ocular and eyelid hygiene, eye surgery, and violations of the posterior segment. Its product portfolio includes eye drops, ophthalmic gels, sterile compresses and micellar solutions. Thea markets these products under the brand names Blephagel, Blephasteam, Nutrof, ABAK, Blephasol, and Blephaclean. The company markets products through sales organizations and distributors. Thea is headquartered in Clermont Ferrand, Auvergne, France.
For a complete picture of Bimatoprost’s drug-specific PTSR and LoA scores, buy the report here.